Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine, mRNA-1195, in Healthy Participants 18 Through 55 Years of Age

NCT05831111 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05831111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05831111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine, mRNA-1195, in Healthy Participants 18 Through 55 Years of Age
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 5, 2023
Completion date
October 13, 2026
Enrollment
482 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

epstein-barr virus infection